S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Lantheus Stock Price, News & Analysis (NASDAQ:LNTH)

$73.71
+5.18 (+7.56%)
(As of 12/8/2023 ET)
Compare
Today's Range
$68.24
$74.38
50-Day Range
$61.58
$76.34
52-Week Range
$47.46
$100.85
Volume
949,969 shs
Average Volume
1.01 million shs
Market Capitalization
$5.05 billion
P/E Ratio
51.55
Dividend Yield
N/A
Price Target
$110.71

Lantheus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
50.2% Upside
$110.71 Price Target
Short Interest
Bearish
7.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.67
Upright™ Environmental Score
News Sentiment
0.75mentions of Lantheus in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.06 M Sold Last Quarter
Proj. Earnings Growth
3.20%
From $5.31 to $5.48 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.91 out of 5 stars

Medical Sector

36th out of 954 stocks

Drug Manufacturers - Specialty & Generic Industry

2nd out of 19 stocks


LNTH stock logo

About Lantheus Stock (NASDAQ:LNTH)

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.

LNTH Stock Price History

LNTH Stock News Headlines

TD Cowen Initiates Coverage on Lantheus (NASDAQ:LNTH)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
The Latest Analyst Ratings for Lantheus Holdings
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Lantheus Holdings Inc LNTH
Lantheus Reports Third Quarter 2023 Financial Results
See More Headlines
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LNTH
Employees
698
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$110.71
High Stock Price Target
$127.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+50.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$28.07 million
Pretax Margin
7.99%

Debt

Sales & Book Value

Annual Sales
$1.21 billion
Cash Flow
$4.73 per share
Book Value
$6.50 per share

Miscellaneous

Free Float
67,462,000
Market Cap
$5.05 billion
Optionable
Optionable
Beta
0.66
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report














LNTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Lantheus stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings
or view top-rated stocks.

What is Lantheus' stock price target for 2024?

7 equities research analysts have issued 12 month price objectives for Lantheus' stock. Their LNTH share price targets range from $100.00 to $127.00. On average, they predict the company's share price to reach $110.71 in the next twelve months. This suggests a possible upside of 50.2% from the stock's current price.
View analysts price targets for LNTH
or view top-rated stocks among Wall Street analysts.

How have LNTH shares performed in 2023?

Lantheus' stock was trading at $50.96 at the start of the year. Since then, LNTH stock has increased by 44.6% and is now trading at $73.71.
View the best growth stocks for 2023 here
.

When is Lantheus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our LNTH earnings forecast
.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) released its earnings results on Thursday, November, 2nd. The medical equipment provider reported $1.29 EPS for the quarter, topping the consensus estimate of $1.19 by $0.10. The medical equipment provider earned $319.95 million during the quarter, compared to analysts' expectations of $315.01 million. Lantheus had a trailing twelve-month return on equity of 70.13% and a net margin of 8.63%.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus issued an update on its FY23 earnings guidance on Thursday, November, 2nd. The company provided EPS guidance of $5.60-$5.70 for the period, compared to the consensus EPS estimate of $5.68. The company issued revenue guidance of $1.245-$1.270 billion, compared to the consensus revenue estimate of $1.26 billion.

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?
When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (3.13%), American Century Companies Inc. (1.90%), Westfield Capital Management Co. LP (1.89%), Invesco Ltd. (1.54%), Northern Trust Corp (1.44%) and Reinhart Partners LLC. (1.32%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Minnie Baylor-Henry, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends
.

How do I buy shares of Lantheus?

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:LNTH) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -